Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma Journal Article

   


Authors: Alperovich, A.; Younes, A.
Article Title: Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma
Abstract: The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL. © Wolters Kluwer Health, Inc. All rights reserved.
Keywords: therapeutic target; brentuximab vedotin; antibody-drug conjugates (adcs); cd30 receptors
Journal Title: The Cancer Journal
Volume: 22
Issue: 1
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2016-01-01
Start Page: 23
End Page: 26
Language: English
DOI: 10.1097/ppo.0000000000000168
PROVIDER: scopus
PUBMED: 26841013
PMCID: PMC5042201
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84957688772&partnerID=40&md5=7b2220c9117a21a1270ab908d1a79e0f
Notes: Review -- Export Date: 3 March 2016 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anas Younes
    319 Younes
  2. Anna Alperovich
    23 Alperovich
Related MSK Work